{"nctId":"NCT04523129","briefTitle":"ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)","startDateStruct":{"date":"2020-12-05","type":"ACTUAL"},"conditions":["Dry Eye Disease"],"count":834,"armGroups":[{"label":"CyclASol Ophthalmic Solution","type":"EXPERIMENTAL","interventionNames":["Drug: CyclASol topical ocular, eye drops"]},{"label":"Vehicle Ophthalmic solution","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle topical ocular, eye drops"]}],"interventions":[{"name":"CyclASol topical ocular, eye drops","otherNames":["Ciclosporine (CSA)"]},{"name":"Vehicle topical ocular, eye drops","otherNames":["Vehicle"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed ICF (Informed Consent Form)\n* Patient-reported history of DED in both eyes\n* Current use of OTC (over-the-counter) and/or artificial tears for dry eye symptoms\n* Ability and willingness to follow instructions, including participation in all study assessments and visits\n\nExclusion Criteria:\n\n* Women who are pregnant, nursing or planning a pregnancy\n* Unwillingness to submit a urine pregnancy test at screening and the last visit (or early termination visit) if of childbearing potential, or unwillingness to use acceptable means of birth control\n* Clinically significant slit-lamp findings or abnormal lid anatomy at screening\n* Ocular/periocular malignancy\n* History of herpetic keratitis\n* Active ocular allergies or ocular allergies that may become active during the study period\n* Ongoing ocular or systemic infection at screening or baseline\n* Wear of contact lenses within 3 months prior to screening or anticipated use of contact lenses during the study\n* Use of topical Cyclosporine A or Liftigrast within 2 months prior to screening\n* Intraocular surgery or ocular laser surgery within the previous 6 months, or have any planned ocular and/or lid surgeries over the study period\n* Presence of uncontrolled systemic diseases\n* Presence of known allergy and/or sensitivity to the study drug or its components\n* Randomized in a previous CyclASol trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Total Corneal Fluorescein Staining","description":"Total Corneal Fluorescein Staining (tCFS) is graded based on the National Eye Institute (NEI) scale. The NEI scale divides the cornea in 5 subregions: central, inferior, superior, nasal, temporal. The score for each region ranges from 0-3; 0 corresponds to no staining (best), 3 corresponds to maximum staining (worst). The total score is the sum of the 5 subregions ranging from 0 (best) - 15 (worst).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.96","spread":"0.146"},{"groupId":"OG001","value":"-3.55","spread":"0.149"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Eye Dryness Score","description":"Eye dryness score is rated on a visual analogue scale (VAS) ranging from 0-100; 0 corresponds to no discomfort and 100 to maximum discomfort.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.2","spread":"1.29"},{"groupId":"OG001","value":"-13.6","spread":"1.31"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Conjunctival Lissamine Green Staining","description":"Conjunctival staining was assessed by the investigator in the nasal and temporal sections. The Oxford Scheme was used for each section, with a possible score of 0-5 for each section, where 0=absent and 5=severe. The nasal and temporal scores were summed, for a possible score of 0-10 for each eye.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.24","spread":"0.078"},{"groupId":"OG001","value":"-0.91","spread":"0.079"}]}]}]},{"type":"SECONDARY","title":"Proportion of Responders in Central Corneal Fluorescein Staining Score","description":"≥ 1 score improvement for cCFS on National Eye Institute (NEI) scale: Central Corneal Fluorescein Staining (cCFS) is graded based on the NEI scale. The NEI scale divides the cornea in 5 subregions: central, inferior, superior, nasal, temporal. The score for each region ranges from 0-3; 0 corresponds to no staining (best), 3 corresponds to maximum staining (worst).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"275","spread":null},{"groupId":"OG001","value":"238","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Responders in Total Corneal Fluorescein Staining Score","description":"≥ 3 scores improvement for tCFS on National Eye Insititute (NEI) scale: Total Corneal Fluorescein Staining (tCFS) is graded based on the NEI scale. The NEI scale divides the cornea in 5 subregions: central, inferior, superior, nasal, temporal. The score for each region ranges from 0-3; 0 corresponds to no staining (best), 3 corresponds to maximum staining (worst). The total score is the sum of the 5 subregions ranging from 0 (best) -15 (worst).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"293","spread":null},{"groupId":"OG001","value":"236","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Central Corneal Fluorescein Staining","description":"Central Corneal Fluorescein Staining (cCFS) is graded based on the National Eye Institute (NEI) scale. The NEI scale divides the cornea in 5 subregions: central, inferior, superior, nasal, temporal. The score for each region ranges from 0-3; 0 corresponds to no staining (best), 3 corresponds to maximum staining (worst).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.79","spread":"0.045"},{"groupId":"OG001","value":"-0.67","spread":"0.046"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Corneal Fluorescein Staining","description":"Total Corneal Fluorescein Staining (tCFS) is graded based on the National Eye Institute (NEI) scale. The NEI scale divides the cornea in 5 subregions: central, inferior, superior, nasal, temporal. The score for each region ranges from 0-3; 0 corresponds to no staining (best), 3 corresponds to maximum staining (worst). The total score is the sum of the 5 subregions ranging from 0 (best) - 15 (worst).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.53","spread":"0.144"},{"groupId":"OG001","value":"-2.97","spread":"0.147"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Visual Analogue Scale (VAS) for Blurred Vision","description":"Blurred vision score is rated on a visual analogue scale (VAS) ranging from 0-100; 0 corresponds to no discomfort and 100 to maximum discomfort.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.1","spread":"1.19"},{"groupId":"OG001","value":"-6.1","spread":"1.21"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":423},"commonTop":["Instillation Site Pain"]}}}